Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $170

Benzinga Newsdesk www.benzinga.com Positive 86.1%

Neg 0% Neu 0% Pos 86.1%

Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $146 to $170.